Enovis Corp Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $2.3B+9.0% YoYTTM through 3 Jul 2026
Net Income -$1.1BTTM through 3 Jul 2026
Free Cash Flow $63.7MTTM through 3 Jul 2026
Margins
| Current | |
|---|---|
| Gross Margin | 59.8% |
| EBITDA Margin | 13.4% |
| Operating Margin | -50.0% |
| Net Margin | -48.0% |
Returns
-79.5%ROE
-30.9%ROA
Balance Sheet Health
Debt / Equity0.87x
Current Ratio2.02x
Net Debt$1.3B
Cash & Equivalents$12.6M
Quality Metrics
Altman Z-Score-0.38
Piotroski F-Score5 / 9
FCF Margin2.8%
Rule of 404.7
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $2.2B
Diluted EPS-$19.30TTMFY2025: $-20.75
Dividend
No dividend
Capital Allocation
R&D Spend$124.3M
Capex Intensity9.0%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Reconstructive | $1.2B | +10.0% | View detailsDriven by extremities, hip, knee, and shoulder reconstructive joint products and surgical productivity tools. |
| Prevention & Recovery | $1.1B | +4.0% | View detailsFocused on orthopedic bracing, soft goods, vascular systems, and hot/cold therapy products. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.